A PYMNTS Company

US/ Israel: Teva ready for regulatory nod for Mylan buy

By  |  May 6, 2015

Generic drugmaker Teva Pharmaceutical Industries Ltd said it could “promptly” divest some operations to obtain regulatory clearance for its proposed $40 billion takeover of smaller rival Mylan NV.

    Get the Full Story

    Complete the form to unlock this article and enjoy unlimited free access to all PYMNTS content — no additional logins required.

    yesSubscribe to our daily newsletter, PYMNTS Today.

    By completing this form, you agree to receive marketing communications from PYMNTS and to the sharing of your information with our sponsor, if applicable, in accordance with our Privacy Policy and Terms and Conditions.

    Teva Pharmaceuticals stated on Tuesday that the regulatory approval for a possible merger with Mylan NV can be expected in as little as four months.

    As previously announced on April 21, 2015, Teva has proposed to acquire Mylan for $82.00 per share, with the consideration to be comprised of approximately 50 percent cash and 50 percent stock. Teva’s proposal for Mylan implies a total equity value of approximately $43 billion.

    Teva’s proposal is contingent on Mylan not completing its proposed acquisition of Perrigo or any alternative transactions.

     

    Full content: Nasdaq

    Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.